Merck MRK is focusing on driving long-term growth through the newer products and a promising set of pipelines as its ...

Merck & Co., Inc. (NYSE:MRK) is one of Goldman Sachs top healthcare stocks. On March 3 at the TD Cowen 46th Annual Health ...

Merck (NYSE:MRK) announced a major reorganization of its Human Health business into two global units focused on Oncology and on Specialty, Pharma & Infectious Diseases. The company named new senior ...

Merck (NYSE:MRK) reported positive Phase 3 SMART trial results for ENFLONSIA, showing protection against RSV in high risk ...

Keytruda sales totaled $5,795 million in Q1 2023, up 17% year-on-year, thanks partly to an increase in its indications for use. At the same time, Robert Davis does not actively use the share buyback ...

TD Cowen 46th Annual Health Care Conference March 3, 2026 1:50 PM ESTCompany ParticipantsCaroline Litchfield - Executive ...

Merck’s search for its next blockbuster product continues to go beyond cancer. The pharmaceutical giant has agreed to pay $10.8 billion to acquire Prometheus Biosciences, a biotech with a Phase ...

Merck & Co. Inc. on Monday gained U.S. regulatory approval for a vaccine that could become a tough competitor to one of Pfizer Inc.’s top-selling products. The Food and Drug Administration on Monday ...

Bulletin: ...WIND ADVISORY NOW IN EFFECT UNTIL 2 PM EDT THIS AFTERNOON... * WHAT...West winds 15 to 25 mph with gusts up to 50 mph. * WHERE...A portion of central ...